Celyad Oncology SA (CYAD.BR)
EUR 0.71
(-7.42%)
EUR 0.71
(-7.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.97 Million EUR | -35.2% |
| 2022 | 15.39 Million EUR | -57.58% |
| 2021 | 36.3 Million EUR | 3.46% |
| 2020 | 35.09 Million EUR | -20.64% |
| 2019 | 44.21 Million EUR | 14.23% |
| 2018 | 38.71 Million EUR | 28.64% |
| 2017 | 30.09 Million EUR | -37.21% |
| 2016 | 47.92 Million EUR | -0.27% |
| 2015 | 48.05 Million EUR | 177.89% |
| 2014 | 17.29 Million EUR | 11.65% |
| 2013 | 15.48 Million EUR | 2.85% |
| 2012 | 15.05 Million EUR | 149.42% |
| 2011 | 6.03 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.58 Million EUR | 0.0% |
| 2023 FY | 26.6 Million EUR | 72.8% |
| 2023 Q4 | 9.97 Million EUR | 0.0% |
| 2023 Q2 | 11.15 Million EUR | 0.0% |
| 2022 Q1 | 32.72 Million EUR | -9.86% |
| 2022 Q4 | 32.03 Million EUR | 0.0% |
| 2022 FY | 15.39 Million EUR | -57.58% |
| 2022 Q2 | 32.49 Million EUR | -0.72% |
| 2021 Q4 | 36.3 Million EUR | -7.28% |
| 2021 Q2 | 37.82 Million EUR | 2.84% |
| 2021 Q1 | 36.78 Million EUR | 4.82% |
| 2021 FY | 36.3 Million EUR | 3.46% |
| 2021 Q3 | 39.15 Million EUR | 3.51% |
| 2020 Q4 | 35.09 Million EUR | 0.0% |
| 2020 Q2 | 45.44 Million EUR | 0.0% |
| 2020 FY | 35.09 Million EUR | -20.64% |
| 2019 Q4 | 44.21 Million EUR | 0.0% |
| 2019 Q2 | 40.43 Million EUR | 0.0% |
| 2019 FY | 44.21 Million EUR | 14.23% |
| 2018 Q4 | 38.71 Million EUR | 0.0% |
| 2018 FY | 38.71 Million EUR | 28.64% |
| 2018 Q2 | 36.37 Million EUR | 0.0% |
| 2017 FY | 30.09 Million EUR | -37.21% |
| 2017 Q2 | 43.04 Million EUR | 0.0% |
| 2017 Q4 | 30.09 Million EUR | 0.0% |
| 2016 FY | 47.92 Million EUR | -0.27% |
| 2016 Q4 | 47.92 Million EUR | 0.0% |
| 2016 Q2 | 43.36 Million EUR | 0.0% |
| 2015 FY | 48.05 Million EUR | 177.89% |
| 2015 Q2 | 58.4 Million EUR | 0.0% |
| 2015 Q4 | 48.05 Million EUR | 0.0% |
| 2014 FY | 17.29 Million EUR | 11.65% |
| 2014 Q2 | 16.12 Million EUR | 0.0% |
| 2014 Q4 | 17.29 Million EUR | 0.0% |
| 2013 Q4 | 15.48 Million EUR | 0.0% |
| 2013 Q2 | 16.16 Million EUR | 0.0% |
| 2013 FY | 15.48 Million EUR | 2.85% |
| 2012 Q4 | 15.05 Million EUR | 0.0% |
| 2012 FY | 15.05 Million EUR | 149.42% |
| 2011 FY | 6.03 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -44.358% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 92.386% |
| Adocia SA | 31.87 Million EUR | 68.692% |
| Aelis Farma SA | 13.08 Million EUR | 23.716% |
| Biophytis S.A. | 15.84 Million EUR | 37.043% |
| Advicenne S.A. | 24.37 Million EUR | 59.068% |
| genOway Société anonyme | 14.45 Million EUR | 30.994% |
| IntegraGen SA | 5.97 Million EUR | -66.862% |
| Medesis Pharma S.A. | 6.42 Million EUR | -55.271% |
| Neovacs S.A. | 3.71 Million EUR | -168.795% |
| NFL Biosciences SA | 3.62 Million EUR | -175.583% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -47.117% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -201.44% |
| Sensorion SA | 13.22 Million EUR | 24.565% |
| Theranexus Société Anonyme | 5.01 Million EUR | -98.916% |
| TME Pharma N.V. | 2.78 Million EUR | -258.276% |
| Valbiotis SA | 13.7 Million EUR | 27.21% |
| TheraVet SA | 1.48 Million EUR | -571.922% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 51.251% |
| argenx SE | 402.79 Million EUR | 97.523% |
| BioSenic S.A. | 32.26 Million EUR | 69.074% |
| DBV Technologies S.A. | 38.74 Million USD | 74.247% |
| Galapagos NV | 1.56 Billion EUR | 99.361% |
| Genfit S.A. | 105.92 Million EUR | 90.58% |
| GeNeuro SA | 20.13 Million EUR | 50.457% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -15.862% |
| Innate Pharma S.A. | 132.29 Million EUR | 92.458% |
| Inventiva S.A. | 101.59 Million EUR | 90.178% |
| MaaT Pharma SA | 22.46 Million EUR | 55.584% |
| MedinCell S.A. | 77.77 Million EUR | 87.17% |
| Nanobiotix S.A. | 95.74 Million EUR | 89.578% |
| Onward Medical N.V. | 25.69 Million EUR | 61.172% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 60.287% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 83.111% |
| Oxurion NV | 19.73 Million EUR | 49.443% |
| Pharming Group N.V. | 228.28 Million EUR | 95.629% |
| Poxel S.A. | 53.9 Million EUR | 81.488% |
| GenSight Biologics S.A. | 34.72 Million EUR | 71.267% |
| Transgene SA | 26.51 Million EUR | 62.371% |
| Financière de Tubize SA | 123.65 Million EUR | 91.93% |
| UCB SA | 6.56 Billion EUR | 99.848% |
| Valneva SE | 341.14 Million EUR | 97.075% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -119.441% |